In a bold move that has captured significant attention, Novo Nordisk has initiated legal action against Hims & Hers, a telehealth provider, claiming infringement on its patent rights related to the highly successful weight-loss medication Wegovy. This lawsuit, filed on February 9, 2026, in a federal court located in Delaware, emerges just days after Hims & Hers announced its intention to market a compounded version of Wegovy at an appealing introductory price of $49 per month.
The controversy took a turn when the Food and Drug Administration (FDA) issued a warning to Hims & Hers, leading the company to announce on February 7 that it would cease the sales of its modified version of the Wegovy pill. For context, Wegovy, which contains the active ingredient semaglutide, stands out as the only FDA-approved glucagon-like peptide-1 (GLP-1) drug available in pill form specifically designed for weight loss. Additionally, semaglutide is marketed under the name Ozempic for individuals with Type 2 diabetes.
Novo Nordisk has leveled serious allegations against Hims & Hers, accusing the telehealth firm of "mass marketing unapproved knock-off versions of Wegovy and Ozempic," a practice that supposedly circumvents the rigorous FDA review process that ensures drug safety and efficacy. John Kuckelman, who serves as Novo's senior vice president and group general counsel, articulated this stance clearly: "That’s dangerous and deceptive to patients, and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective."
Furthermore, Novo claims that Hims & Hers continues to engage in the unlawful large-scale compounding of injectable versions of their FDA-approved medications, a practice that potentially jeopardizes patient health and well-being. As of now, representatives from Hims & Hers have not provided responses to inquiries from USA TODAY regarding the ongoing lawsuit.
It is essential to note that the FDA has permitted compounding pharmacies to produce copies of certain drugs when there are shortages. In February 2025, the FDA declared that the shortage of semaglutide had come to an end, subsequently setting timelines for enforcement actions against compounding pharmacies and facilities that effectively replicate Novo's drug.
On February 6, the FDA announced its intention to take steps to restrict the use of GLP-1 ingredients in compounded drugs marketed by Hims & Hers, along with other companies and online pharmacies. This decision stems from growing concerns about the quality, safety, and effectiveness of these compounded products.
But here's where it gets controversial: Are we prioritizing innovation and patient safety, or are we stifling access to affordable treatment options? We invite you to share your thoughts. Do you agree with Novo's stance, or do you believe that companies like Hims & Hers should be allowed to provide alternative solutions?
